# Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

> **NCT00118612** · PHASE2 · COMPLETED · sponsor: **Allergy Therapeutics** · enrollment: 68 (actual)

## Conditions studied

- Type I Hypersensitivity

## Interventions

- **BIOLOGICAL:** Tree MATA MPL - Therapeutic Regimen
- **BIOLOGICAL:** Tree MATA MPL - Intermediate dose
- **BIOLOGICAL:** Tree MATA MPL - Low dose
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00118612
- **Lead sponsor:** Allergy Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07-07
- **Primary completion:** 2005-09-15
- **Final completion:** 2005-09-15
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118612, "Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00118612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*